Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377333 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT05377333 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 94 participants.
The verdict
NCT05377333, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.
Interventions
- DRUG Placebo
- DRUG LY3457263
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2023-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05377333
The ClinicalTrials.gov registry entry for NCT05377333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05377333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05377333 about?
NCT05377333 is a clinical study titled "A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes". The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the bod...
What is the current status of trial NCT05377333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2022-06-02. Estimated completion is 2023-11-22.
What interventions are being tested in trial NCT05377333?
The interventions under investigation include: Placebo (DRUG), LY3457263 (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT05377333?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.